Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase

Molecular Pharmacology

Volumn 59, Issue 2, 2001, Pages 285-293

  Degrève, Bart ^a   Esnouf, Robert ^b   De Clercq, Erik ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ASPARAGINE; BUCICLOVIR; GANCICLOVIR; GLYCINE; LOBUCAVIR; PENCICLOVIR; PYRIMIDINE NUCLEOTIDE; SORIVUDINE; THYMIDINE DERIVATIVE; THYMIDYLATE KINASE; THYMINE ARABINOSIDE; UNCLASSIFIED DRUG; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING COMPETITION; DRUG POTENCY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0035139165     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.2.285     Document Type: Article

References (46)

1. Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase, comparison of secondary structure predictions and conservation
2. Strategies for the measurement of the inhibitory effects of thymidine analogs on the activity of thymidylate synthase in intact murine leukemia L1210 cells
3. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2bremovinyl)-2′-deoxyuridine and related compounds
4. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-Bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 and type 2 thymidine kinase gene
5. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other anti_herpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2
6. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells
7. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy
8. Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: Analysis of selected mutants in vitro
9. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy
10. Crystal structures of the thymldine kinase from herpes simplex virus type-I in complex with deoxythymidine and ganciclovir
11. Green fluorescent protein as a marker for gene expression
12. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
13. Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer
14. Bystander effect of purine nucleoside analogues in HSV-1 tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues
15. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine
16. Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: Molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK
17. Differential ganciclovir-mediated cell killing by glutamine 125 mutants of herpes simplex virus type 1 thymidine kinase
18. A fast method for obtaining highly pure recombinant herpes simplex virus type 1 thymidine kinase
19. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
20. In situ use of suicide genes for cancer therapy
21. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus
22. Viral thymidine kinases and their relatives
23. Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities
24. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy
25. Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster
26. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant
27. Drug resistance of herpes simplex virus type 1 - Structural considerations at the molecular level of the thymidine kinase
28. Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1
29. Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity
30. The equine herpes virus 4 thymidine kinase is a better suicide gene than the human herpes virus 1 thymidine kinase
31. Ganciclovir. An update of its therapeutic use cytomegalovirus infection
32. Site-directed mutagenesis of herpes simplex virus type 1 thymidine kinase opposes the importance of amino acid positions 251, 321 and 348 for selective recognition of substrate analogs
33. Herpes simplex virus isolates from an immunocompromised patient who failed to respond to acyclovir treatment express thymidine kinase with altered substrate specificity
34. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats
35. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats
36. Therapy of malignant brain tumors by intratumoraI implantation of retroviral vector-producing cells
37. Proteolytic mapping of the thymidine/ thymidylate binding site of herpes simplex virus type 1 thymidine kinase: A general photoaffinity labeling method for identifying active-site peptides
38. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate
39. Chimeric green fluorescent protein as a tool for visualizing subcellular organelles in living cells
40. Human gene marker/therapy clinical protocols
41. Perspectives on the design and biochemical pharmacology of inhibiters of thymidylate synthetase
42. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells
43. Establishment of mutant murine mammary carcinoma FM3A cell strains transformed with the herpes simplex virus type 2 thymidine kinase gene
44. Gene delivery to glioma cells in rat brain by graining of a retrovirus packaging cell line
45. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
46. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2′-deoxyuridine